Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma

Lung Cancer

Volumn 85, Issue 3, 2014, Pages 429-434

  Krug, L M ^a   Wozniak, A J ^b   Kindler, H L ^c   Feld, R ^d   Koczywas, M ^e   Morero, J L ^f   Rodriguez, C P ^g   Ross, H J ^h   Bauman, J E ⁱ   Orlov, S V ^j   Ruckdeschel, J C ^k   Mita, A C ^l   Fein, L ^m   He, X ⁿ   Hall, R ⁿ   Kawabe, T ^o   Sharma, S ^p  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f Directora del departamento de EPID   (Argentina)

^g UNIVERSITY OF WASHINGTON   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF NEW MEXICO   (United States)

^j PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^k INTERMOUNTAIN HEALTHCARE   (United States)

^l CEDARS SINAI MEDICAL CENTER   (United States)

^m Centro Oncologico de Rosario   (Argentina)

ⁿ ICON CLINICAL RESEARCH   (United States)

^o CanBas Co Ltd   (Japan)

^p UNIVERSITY OF UTAH   (United States)

more..

Author keywords

CBP501; CDC25C; Cisplatin; DNA repair; Malignant pleural mesothelioma; Randomized phase II trial

Indexed keywords

ANTINEOPLASTIC AGENT; CBP 501; CISPLATIN; CREATININE; PEMETREXED; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; CDC25C PHOSPHATASE (211-221); GLUTAMIC ACID DERIVATIVE; GUANINE; PEPTIDE FRAGMENT; PROTEIN TYROSINE PHOSPHATASE;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DYSGEUSIA; FEBRILE NEUTROPENIA; FEMALE; HICCUP; HUMAN; HYPERGLYCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INFUSION RELATED REACTION; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CDC25 PHOSPHATASES; CISPLATIN; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE FRAGMENTS; TREATMENT OUTCOME;

EID: 84926408126     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.06.008     Document Type: Article

References (12)

1. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
2. Peng C.Y., Graves P.R., Thoma R.S., Wu Z., Shaw A.S., Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997, 277:1501-1505.
3. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004, 3:513-519.
4. Sha S.K., Sato T., Kobayashi H., Ishigaki M., Yamamoto S., Sato H., et al. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol Cancer Ther 2007, 6:147-153.
5. Mine N., Yamamoto S., Saito N., Yamazaki S., Suda C., Ishigak M., et al. CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin. Mol Cancer Ther 2011, 10:1929-1938.
6. Shapiro G.I., Tibes R., Gordon M.S., Wong M.S., Eder J.P., Borad M.J., et al. Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. Clin Cancer Res 2011, 17:3431-3442.
7. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham J., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
8. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15:257-260.
9. Francart J., Legrand C., Sylvester R., Van Glabbeke M., Van Meerbeeck J.P., Robert A. Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma - The EORTC Lung Cancer Group. J Clin Oncol 2006, 24:3007-3012.
10. A'Hern R.P. Sample size tables for exact single-stage phase II designs. Stat Med 2001, 20:859-866.
11. Fleming T.R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38:143-151.
12. Santoro A., O'Brien M.E., Stahel R.A., Nackaerts K., Baas P., Karthaus M., et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008, 3:756-763.